Scholarlink

<p>Dermatophytes cause a wide range of superficial infections of the skin, hair and nails, with high global prevalence and considerable public health relevance. Treatment regimens for dermatophytosis are limited to few antifungal drug classes, and rising resistance—particularly to terbinafine—further compromises therapeutic efficacy. Topical antiseptics such as octenidine (OCT) may represent a promising option for infection control and local therapy. This study investigated the in vitro antifungal activity of the pure antiseptic OCT (at final assay concentrations of 0.1% and 0.05%) and two OCT-based commercial ready-to-use medicinal products (octeniderm® and octenisept®) against clinical isolates of emerging (drug-resistant) dermatophytes including <i>Trichophyton rubrum, T. mentagrophytes, T. tonsurans, T. interdigitale, T. indotineae</i> and <i>Microsporum canis</i>. Quantitative suspension assays were conducted according to EN 13624:2013 under low organic load (0.3&#xa0;g/L bovine serum albumin) and high organic load (3&#xa0;g/L bovine serum albumin, 3&#xa0;mL/L defibrinated sheep blood), with contact times ranging from 1 to 15&#xa0;min. Results showed that the active OCT itself as well as the skin antiseptic octeniderm® and the wound and mucous membrane antiseptic octenisept® are effective against the tested dermatophytes in a time- and concentration-dependent manner. Notably, octeniderm® was able to inhibit fungal growth within 1&#xa0;min, even under high organic load conditions. These in vitro findings suggest that OCT, a well-tolerated antiseptic already in clinical use represents a potential option for preventing transmission and managing superficial infections caused by (drug-resistant) dermatophytes</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In Vitro Antifungal Activity of Octenidine Against Emerging Dermatophyte Species

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月16日

查看全文
  • Kathrin Spettel,
  • Richard Kriz,
  • Sarah Fellhuber,
  • Madita Loy,
  • Hannah Tiefenbrunner,
  • Melanie Schabransky,
  • Sonia Galazka,
  • Birgit Willinger

摘要

Dermatophytes cause a wide range of superficial infections of the skin, hair and nails, with high global prevalence and considerable public health relevance. Treatment regimens for dermatophytosis are limited to few antifungal drug classes, and rising resistance—particularly to terbinafine—further compromises therapeutic efficacy. Topical antiseptics such as octenidine (OCT) may represent a promising option for infection control and local therapy. This study investigated the in vitro antifungal activity of the pure antiseptic OCT (at final assay concentrations of 0.1% and 0.05%) and two OCT-based commercial ready-to-use medicinal products (octeniderm® and octenisept®) against clinical isolates of emerging (drug-resistant) dermatophytes including Trichophyton rubrum, T. mentagrophytes, T. tonsurans, T. interdigitale, T. indotineae and Microsporum canis. Quantitative suspension assays were conducted according to EN 13624:2013 under low organic load (0.3 g/L bovine serum albumin) and high organic load (3 g/L bovine serum albumin, 3 mL/L defibrinated sheep blood), with contact times ranging from 1 to 15 min. Results showed that the active OCT itself as well as the skin antiseptic octeniderm® and the wound and mucous membrane antiseptic octenisept® are effective against the tested dermatophytes in a time- and concentration-dependent manner. Notably, octeniderm® was able to inhibit fungal growth within 1 min, even under high organic load conditions. These in vitro findings suggest that OCT, a well-tolerated antiseptic already in clinical use represents a potential option for preventing transmission and managing superficial infections caused by (drug-resistant) dermatophytes